Clay Siegall, CEO and President of Seattle Genetics has recently claimed in an interview new strides for genetic based cancer treatments. Using their 20% increase in revenues since last year, Seattle Genetics is going into Phase 3 trials for CD-30 expressing lymphomas and running five trials for their lead clinical stage program SGN-CD33A which includes an emphasis on survival and recovery in older patients. Additionally, the company is using these profits to do research into other genetic cancers, such as SGN-LIV1A breast cancer.
Dr. Siegall has a PhD from George Washington University in genetics, and is one of the co-founders of Seattle Genetics, which started in 1998 as a team of scientists who focus on specifically targeted cancer therapies. The company exists for both advancing the scientific study and treatment of aggressive cancers as well as patient care. The company he runs is involved with GlaxoSmithKline and Pfizer among others where the new treatments are licensed out to reach as many people as possible. Before co-foundng Seattle Genetics, Dr. Clay Siegall has a long history of working in the medical industry, having been a member at the National Institute of Health, the National Cancer Institute (NCI), and Bristol-Myers Squibb.
Seattle Genetics currently has 20 treatments, known as anibody-drug conjugates (ADCs) due to the treatment using both targeted antibodies and pharmaceuticals in clinical trials and is worth over $675 million. Having gone public in 2001, the company has only grown and developed into a driving force in cancer treatment, centered in Washington State.